Arcellx Inc

Common Name

Arcellx

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

163

Ticker

ACLX

Exchange

NASDAQ/NGS

Website

www.arcellx.com

Description

Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to h... Show more

Financial Statements of Arcellx

Below are the financial statements of Arcellx, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	105.68^a	394.58^a
Marketable securities	481.7^a	307.43^a
Restricted cash, current	0.21^a	1.9^a
Prepaid expenses and other current assets	11.73^a	12.44^a
Total current assets	599.31^a	716.36^a
Assets	—	—
Restricted cash, non-current	2.42^a	2.42^a
Marketable securities, non-current	38.28^a	27.17^a
Property and equipment, net	46.46^a	42.73^a
Operating lease right-of-use assets	23.79^a	27.1^a
Prepaid research and development expenses and other long-term assets	1.08^a	9.36^a
Total assets	711.33^a	825.13^a
Current liabilities	—	—
Accounts payable	2.1^a	2.62^a
Accrued liabilities	56.72^a	18.3^a
Operating lease liabilities, current portion	7.31^a	7.5^a
Finance lease liabilities, current portion	0.23^a	39.28^a
Contract liability to related party	59.06^a	50.53^a
Total current liabilities	125.41^a	118.24^a
Liabilities and stockholders’ equity	—	—
Operating lease liabilities, net of current portion	46.54^a	50.84^a
Contract liabilities, net of current portion to related party	76^a	170.67^a
Other non-current liabilities	8.59^a	0^a
Total liabilities	256.54^a	339.75^a
Stockholders’ equity	—	—
Common stock	0.05^a	0.05^a
Additional paid-in capital	950.72^a	874.26^a
Accumulated other comprehensive income	0.85^a	0.55^a
Accumulated deficit	-496.83^a	-389.48^a
Total stockholders’ equity	454.79^a	485.38^a
Total liabilities and stockholders’ equity	711.33^a	825.13^a

Verified Sources Behind Arcellx’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Arcellx’s data sources below and access millions more through our Disclosure Search.

a. Arcellx's 10-K 2024

Trace every data point back to Arcellx’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Arcellx Inc

Financial Statements of Arcellx

Verified Sources Behind Arcellx’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Kymera Therapeutics Inc

Vericel Corp

Blueprint Medicines Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc